NIH selection propels Cardax towards expansion

The CEO of Cardax Inc. said the selection of the company's astaxanthin compound CDX-085 to take part in the National Institute on Aging's anti-aging interventions testing program will have positive implications for the Hawaii-based business. The program, among the top aging research programs in the U.S., is funded by the National Institutes of Health and only selects 4-5 compounds every year through extensive screening for their potential impact on lifespan extension and their ability to delay disease…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news